2011 Scrip 100: Experimental collaboration model to drive Merck cancer research
This article was originally published in Scrip
In May 2010, Merck & Co launched an oncology collaborative trials network (Onconet) with leading international cancer research centres to speed up the development of its drug and vaccine candidates. The global research sites will lead the design and conduct of Phase 0 to Phase IIa clinical studies of Merck's investigational oncology candidates. Merck says that every year, the network will enrol approximately 1,200 patients in 30 to 40 clinical trials.
You may also be interested in...
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
The company is the second big medtech to announce a major investment in R&D in the country in 2020.